• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌中细胞因子存在时对雄激素及雄激素受体拮抗剂的反应

Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer.

作者信息

Culig Zoran

机构信息

Experimental Urology, Department of Urology, Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria.

出版信息

Cancers (Basel). 2021 Jun 12;13(12):2944. doi: 10.3390/cancers13122944.

DOI:10.3390/cancers13122944
PMID:34204596
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8231240/
Abstract

Non-steroidal anti-androgens have a major role in the treatment of non-localized prostate cancer. Interleukins are involved in the regulation of many cellular functions in prostate cancer and also modify cellular response to anti-androgens. A specific role of selected IL is presented in this review. IL-8 is a cytokine expressed in prostate cancer tissue and microenvironment and promotes proliferation and androgen receptor-mediated transcription. In contrast, IL-1 displays negative effects on expression of androgen receptor and its target genes. A subgroup of prostate cancers show neuroendocrine differentiation, which may be in part stimulated by androgen ablation. A similar effect was observed after treatment of cells with IL-10. Another cytokine which is implicated in regulation of androgenic response is IL-23, secreted by myeloid cells. Most studies on androgens and IL were carried out with IL-6, which acts through the signal transducer and activator of the transcription (STAT) factor pathway. IL-6 is implicated in resistance to enzalutamide. Activation of the STAT-3 pathway is associated with increased cellular stemness. IL-6 activation of the androgen receptor in some prostate cancers is associated with increased growth in vitro and in vivo. Molecules such as galiellalactone or niclosamide have an inhibitory effect on both androgen receptor and STAT-3 pathways.

摘要

非甾体类抗雄激素药物在非局限性前列腺癌的治疗中发挥着重要作用。白细胞介素参与前列腺癌多种细胞功能的调节,还会改变细胞对抗雄激素药物的反应。本综述介绍了特定白细胞介素的具体作用。白细胞介素-8是一种在前列腺癌组织和微环境中表达的细胞因子,可促进增殖以及雄激素受体介导的转录。相比之下,白细胞介素-1对雄激素受体及其靶基因的表达具有负面影响。一部分前列腺癌表现出神经内分泌分化,这可能部分是由雄激素剥夺刺激所致。用白细胞介素-10处理细胞后也观察到了类似的效果。另一种与雄激素反应调节有关的细胞因子是由髓样细胞分泌的白细胞介素-23。大多数关于雄激素和白细胞介素的研究是针对白细胞介素-6进行的,它通过信号转导和转录激活因子(STAT)途径发挥作用。白细胞介素-6与恩杂鲁胺耐药有关。STAT-3途径的激活与细胞干性增加有关。在一些前列腺癌中,白细胞介素-6对雄激素受体的激活与体内外生长增加有关。诸如加列内酯或氯硝柳胺等分子对雄激素受体和STAT-3途径均有抑制作用。

相似文献

1
Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer.前列腺癌中细胞因子存在时对雄激素及雄激素受体拮抗剂的反应
Cancers (Basel). 2021 Jun 12;13(12):2944. doi: 10.3390/cancers13122944.
2
Interleukin-6 Function and Targeting in Prostate Cancer.白细胞介素 6 在前列腺癌中的功能和靶向作用。
Adv Exp Med Biol. 2021;1290:1-8. doi: 10.1007/978-3-030-55617-4_1.
3
Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer.雄激素受体共激活因子在前列腺癌生长和分化调控中的作用
J Cell Physiol. 2016 Feb;231(2):270-4. doi: 10.1002/jcp.25099.
4
SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells.信号转导和转录激活因子3(SOCS3)调节前列腺癌细胞对恩杂鲁胺的反应,并受雄激素受体信号和CpG甲基化调控。
Mol Cancer Res. 2016 Jun;14(6):574-85. doi: 10.1158/1541-7786.MCR-15-0495. Epub 2016 Apr 6.
5
Interleukin-6 and prostate cancer: Current developments and unsolved questions.白细胞介素-6 与前列腺癌:最新进展与未解问题
Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):25-30. doi: 10.1016/j.mce.2017.03.012. Epub 2017 Mar 16.
6
Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.核因子κB p50/p65、Fra-1和JunD的组成性激活对于前列腺癌中白细胞介素6表达失调至关重要。
Cancer Res. 2003 May 1;63(9):2206-15.
7
p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.在长期用白细胞介素-6处理的前列腺癌细胞中,p300调节前列腺特异性抗原的雄激素受体非依赖性表达。
Cancer Res. 2005 Jul 1;65(13):5965-73. doi: 10.1158/0008-5472.CAN-04-2837.
8
[Molecular mechanisms involved in hormone resistance of prostate cancer].[前列腺癌激素抵抗所涉及的分子机制]
Bull Cancer. 2004 Oct;91(10):747-57.
9
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.STAT3 抑制剂 Galiellalactone 降低良性和恶性前列腺模型中 IL6 介导的 AR 活性。
Mol Cancer Ther. 2018 Dec;17(12):2722-2731. doi: 10.1158/1535-7163.MCT-18-0508. Epub 2018 Sep 25.
10
Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.白细胞介素6通过信号转导和转录激活因子3依赖性途径激活LNCaP前列腺癌细胞中雄激素受体介导的基因表达。
Cancer Res. 2000 Apr 15;60(8):2132-5.

引用本文的文献

1
The immune landscape of systemic inflammation in prostate cancer.前列腺癌全身炎症的免疫格局。
Cancer Biol Med. 2025 Sep 4;22(8). doi: 10.20892/j.issn.2095-3941.2025.0149.
2
Dynamic Soluble IL-6R/Soluble gp130 Ratio as a Potential Indicator for the Prostate Malignancy Phenotype-A Multicenter Case-Control Study.动态可溶性白细胞介素-6受体/可溶性糖蛋白130比值作为前列腺恶性表型的潜在指标——一项多中心病例对照研究
J Pers Med. 2024 Sep 28;14(10):1037. doi: 10.3390/jpm14101037.
3
Evidence of the Link between Stroma Remodeling and Prostate Cancer Prognosis.基质重塑与前列腺癌预后之间联系的证据。
Cancers (Basel). 2024 Sep 21;16(18):3215. doi: 10.3390/cancers16183215.
4
Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance.靶向前列腺癌中的白细胞介素-8及其受体:炎症、应激反应与治疗抵抗
Cancers (Basel). 2024 Aug 8;16(16):2797. doi: 10.3390/cancers16162797.
5
Inflammation in Prostate Cancer: Exploring the Promising Role of Phenolic Compounds as an Innovative Therapeutic Approach.前列腺癌中的炎症:探索酚类化合物作为一种创新治疗方法的潜在作用。
Biomedicines. 2023 Nov 24;11(12):3140. doi: 10.3390/biomedicines11123140.
6
Angiogenic systemic response to the hypoxic microenvironment in prostate tumorigenesis: A pilot study.前列腺肿瘤发生过程中对缺氧微环境的血管生成性全身反应:一项初步研究。
Exp Ther Med. 2023 Sep 1;26(4):483. doi: 10.3892/etm.2023.12182. eCollection 2023 Oct.
7
Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective.剖析雄激素剥夺疗法对晚期前列腺癌钙黏蛋白转换的影响:分子视角。
Oncol Res. 2023 Jan 12;30(3):137-155. doi: 10.32604/or.2022.026074. eCollection 2022.
8
LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF-κB and STAT3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects.氧化低密度脂蛋白通过激活 LOX-1 诱导 NF-κB 和 STAT3 信号通路诱导 AR 和 AR-V7 的表达,从而降低恩杂鲁胺的细胞毒性作用。
Int J Mol Sci. 2023 Mar 7;24(6):5082. doi: 10.3390/ijms24065082.
9
Role of Interleukin-1 family in bone metastasis of prostate cancer.白细胞介素-1家族在前列腺癌骨转移中的作用
Front Oncol. 2022 Sep 27;12:951167. doi: 10.3389/fonc.2022.951167. eCollection 2022.
10
The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521.高危前列腺癌中预处理免疫状态对放射治疗反应的影响:NRG/RTOG 0521 的验证性研究。
Int J Radiat Oncol Biol Phys. 2022 Oct 1;114(2):266-274. doi: 10.1016/j.ijrobp.2022.05.048. Epub 2022 Jun 5.

本文引用的文献

1
Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence.慢性 IL-1 暴露促使 LNCaP 细胞发生雄激素和 AR 非依赖性演变。
PLoS One. 2020 Dec 16;15(12):e0242970. doi: 10.1371/journal.pone.0242970. eCollection 2020.
2
Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells.白细胞介素-10诱导前列腺癌细胞中神经内分泌标志物和程序性死亡受体1的表达。
Prostate Cancer. 2020 Jul 31;2020:5305306. doi: 10.1155/2020/5305306. eCollection 2020.
3
Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells.白细胞介素-23 抑制雄激素受体拮抗剂恩扎鲁胺和达罗鲁胺诱导的去势抵抗性前列腺癌细胞衰老水平。
Horm Cancer. 2020 Aug;11(3-4):182-190. doi: 10.1007/s12672-020-00391-5. Epub 2020 Jun 20.
4
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.针对 CXCR2 阻断以治疗耐药性前列腺癌的细胞异质性。
Sci Transl Med. 2019 Dec 4;11(521). doi: 10.1126/scitranslmed.aax0428.
5
RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.RELA 足以介导白细胞介素 1 对 LNCaP 疾病进展模型中雄激素受体表达和活性的抑制作用。
Prostate. 2020 Feb;80(2):133-145. doi: 10.1002/pros.23925. Epub 2019 Nov 15.
6
IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer.IL8 表达与原发性和转移性前列腺癌中的前列腺癌侵袭性和雄激素受体缺失相关。
Mol Cancer Res. 2020 Jan;18(1):153-165. doi: 10.1158/1541-7786.MCR-19-0595. Epub 2019 Oct 11.
7
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.STAT3 抑制剂 Galiellalactone 降低良性和恶性前列腺模型中 IL6 介导的 AR 活性。
Mol Cancer Ther. 2018 Dec;17(12):2722-2731. doi: 10.1158/1535-7163.MCT-18-0508. Epub 2018 Sep 25.
8
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.髓细胞分泌的白细胞介素-23 驱动去势抵抗性前列腺癌。
Nature. 2018 Jul;559(7714):363-369. doi: 10.1038/s41586-018-0266-0. Epub 2018 Jun 27.
9
Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.前列腺癌相关成纤维细胞(CAFs)中雄激素受体信号的丧失促进 CCL2 和 CXCL8 介导的癌细胞迁移。
Mol Oncol. 2018 Aug;12(8):1308-1323. doi: 10.1002/1878-0261.12327. Epub 2018 Jul 10.
10
Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1.Sprouty2 缺失诱导的 IL6 通过清道夫受体 B1 驱动去势抵抗性前列腺癌。
EMBO Mol Med. 2018 Apr;10(4). doi: 10.15252/emmm.201708347.